Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.

NCT00761280 is registered in ClinicalTrials.gov with Isarna Therapeutics GmbH as lead sponsor.

NCT NCT00761280
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00761280 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.
Lead sponsor
Isarna Therapeutics GmbH
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2008
Completion date
June 30, 2012
Enrollment
27 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, glioblastoma